Tag - STTK

Developments

Shattuck announces Phase 1 results for SL-325 antibody

Shattuck Labs (NASDAQ: STTK) has announced data from its Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics, and immunogenicity of SL-325, its lead DR3 blocking...

June 8, 2026

Markets

HCW starts Shattuck Labs at buy; PT $28

H.C. Wainwright initiated coverage of Shattuck Labs (NASDAQ:STTK) with a “buy” rating and price target of $28. The stock closed at $3.84 on April 29. To overcome the shortcomings of current immunomodulatory cancer...

May 2, 2022

Tag - STTK

Shattuck announces Phase 1 results for SL-325 antibody

HCW starts Shattuck Labs at buy; PT $28

Subscribe